Bicarbonate

Bicarbonate

SCHEMBL378701

CCN(CC)CC.CCN(CC)CC.O=C(O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.44
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CA9 Q16790 3/20 0.39
CA2 P00918 2/20 0.39
CA1 P00915 2/20 0.39
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
AGTR1 P30556 1/20 0.37
LMNA P02545 2/20 0.36
TDP1 Q9NUW8 3/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL60768 1.00 FFAR3 (0.44) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL4800886 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL28088226 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL28103153 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL4800891 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL4312446 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL28065786 0.96 FFAR3 (0.41) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL10783748 0.93 ALDH1A1 (0.40) FFAR3CHRM2CHRM4CHRM5CHRM1
Bicarbonate SCHEMBL28333973 0.93 FFAR3 (0.39) FFAR3CHRM2CHRM4CHRM5CHRM1
Isobutane SCHEMBL27500548 0.90 CHRM2 (0.43) FFAR3CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091106-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING STABILIZED ENVELOPED VIRUSES BY SPRAY-DRYING AND LYOPHILIZATION UNIV COLORADO REGENTS (US) 2026-04-02 US claimed
US-20260014251-A1 COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE VITRIVAX INC (US) 2026-01-15 US claimed
US-20260014093-A1 ATOMIC LAYER DEPOSITION (ALD) PROCESSES APPLIED TO PHAGE AND PHAGE-LIKE PARTICLE PLATFORM YIELD THERMOSTABLE THERAPEUTIC AGENTS UNIV COLORADO REGENTS (US) 2026-01-15 US claimed
EP-4651855-A1 COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE Vitrivax, Inc. (US) 2025-11-26 EP claimed
US-20250352633-A1 COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE BROAD-SPECTRUM HUMAN PAPILLOMAVIRUS FORMULATIONS UNIV COLORADO REGENTS (US) 2025-11-20 US claimed
US-12447127-B2 Thermostable vaccine compositions and methods of preparing the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-10-21 US claimed
US-12303602-B2 Compositions, methods and uses for thermally stable multi-targeted antigens THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2025-05-20 US claimed
WO-2025029323-A1 COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE VITRIVAX, INC. (US) 2025-02-06 WO claimed
WO-2024211446-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING STABILIZED ENVELOPED VIRUSES BY SPRAY-DRYING AND LYOPHILIZATION THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2024-10-10 WO claimed
US-12097291-B2 Thermostable vaccine compositions and methods of preparing same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2024-09-24 US claimed
WO-2012158978-A1 THERMOSTABLE VACCINE COMPOSITIONS AND METHODS OF PREPARING SAME SOLIGENIX, INC. (US) 2012-11-22 WO claimed
EP-2066653-B1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS ROTTAPHARM SPA (IT) 2012-09-12 EP claimed
JP-2011524383-A 2011-09-01 JP claimed
US-20110118289-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS ROTTAPHARM S.P.A. (IT) 2011-05-19 US claimed
EP-2315588-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS Rottapharm S.p.A. (IT) 2011-05-04 EP claimed
WO-2009152868-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS ROTTAPHARM S.P.A. (IT) 2009-12-23 WO claimed
US-20090264451-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS ROTTAPHARM S.P.A. (IT) 2009-10-22 US claimed
EP-2066653-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS Rottapharm S.p.A. (IT) 2009-06-10 EP claimed
WO-2008014822-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS ROTTAPHARM S.P.A. (IT) 2008-02-07 WO claimed
US-4844744-A Liquid, phosphate-free single phase degreasing compositions HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1989-07-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014251-A1 COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE TREH, PNP, RNGTT FFAR3 3188/4885CHRM2 4510/4885CHRM4 3772/4885
US-20090264451-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS IL1A, IL6, IL1B FFAR3 939/4885CHRM2 2309/4885CHRM4 3266/4885
US-20260014093-A1 ATOMIC LAYER DEPOSITION (ALD) PROCESSES APPLIED TO PHAGE AND PHAGE-LIKE PARTICLE PLATFORM YIELD THERMOSTABLE THERAPEUTIC AGENTS ALDOA, AGL, SORD FFAR3 4163/4885CHRM2 1232/4885CHRM4 1554/4885
US-20110118289-A1 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS OPRM1, OPRD1, HTR3C FFAR3 228/4885CHRM2 44/4885CHRM4 70/4885
US-20260091106-A1 COMPOSITIONS AND METHODS FOR MAKING AND USING STABILIZED ENVELOPED VIRUSES BY SPRAY-DRYING AND LYOPHILIZATION CFD, TREH, TMED2 FFAR3 1866/4885CHRM2 4580/4885CHRM4 4169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.